We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $977M
1-Year Est. Return 110.37%
This Fund
S&P 500
This Quarter Est. Return
+25%
1 Year Est. Return
+110.37%
3 Year Est. Return
+306.38%
5 Year Est. Return
+741.86%
10 Year Est. Return
–
AUM
$977M
AUM Growth
+$7.19M
Cap. Flow
-$105M
Cap. Flow %
-10.73%
Top 10 Hldgs %
33.49%
Holding
108
New
18
Increased
27
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
INBX icon
Inhibrx
INBX
+$25.7M
2
UNH icon
UnitedHealth
UNH
+$20.7M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$13.2M
4
VRDN icon
Viridian Therapeutics
VRDN
+$13.2M
5
DRUG
Bright Minds Biosciences
DRUG
+$13M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$36.9M
2
SYK icon
Stryker
SYK
+$27.4M
3
QGEN icon
Qiagen
QGEN
+$20M
4
ABBV icon
AbbVie
ABBV
+$16.3M
5
BSX icon
Boston Scientific
BSX
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Industrials 0.82%
3 Miscellaneous 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBX
1
MBX Biosciences
MBX
$3.03B
$44.2M 4.52%
800,173
+136
+0% +$4.75K
LLY icon
2
Eli Lilly
LLY
$1T
$42M 4.3%
35,000
+384
+1% +$392K
CVS icon
3
CVS Health
CVS
$122B
$40.5M 4.15%
391,791
+4,485
+1% +$400K
DXCM icon
4
DexCom
DXCM
$31.7B
$36M 3.69%
534,767
-155,055
-22% -$10.3M
PTCT icon
5
PTC Therapeutics
PTCT
$5.64B
$35.5M 3.64%
435,691
+4,327
+1% +$312K
RCUS icon
6
Arcus Biosciences
RCUS
$3.63B
$28.3M 2.9%
919,266
-288,008
-24% -$7.12M
GPCR icon
7
Structure Therapeutics
GPCR
$2.94B
$26.1M 2.67%
485,661
+253,568
+109% +$11.2M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.58B
$25.3M 2.59%
1,377,576
+819,640
+147% +$13.2M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.07B
$24.8M 2.54%
669,046
+265,521
+66% +$8.05M
INBX icon
10
Inhibrx
INBX
$1.66B
$24.3M 2.49%
+256,950
New +$25.7M
XENE icon
11
Xenon Pharmaceuticals
XENE
$5.71B
$24M 2.46%
397,379
-99,656
-20% -$5.53M
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.71B
$23.4M 2.4%
577,036
+254,208
+79% +$8.76M
UNH icon
13
UnitedHealth
UNH
$353B
$23.2M 2.38%
+55,921
New +$20.7M
SYK icon
14
Stryker
SYK
$106B
$21.4M 2.19%
67,973
-86,798
-56% -$27.4M
IQV icon
15
IQVIA
IQV
$42.3B
$20.4M 2.09%
105,811
+19,109
+22% +$3.33M
ZBH icon
16
Zimmer Biomet
ZBH
$18B
$20M 2.05%
232,557
-37,000
-14% -$3.24M
PODD icon
17
Insulet
PODD
$9.57B
$20M 2.05%
131,378
-25,183
-16% -$4.2M
ASMB icon
18
Assembly Biosciences
ASMB
$669M
$19.8M 2.03%
721,181
+309,954
+75% +$8.44M
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.77B
$19.2M 1.96%
877,256
-24,255
-3% -$504K
EYPT icon
20
EyePoint Inc
EYPT
$374M
$18.4M 1.89%
1,288,163
-66,637
-5% -$892K
THC icon
21
Tenet Healthcare
THC
$21.7B
$18.2M 1.86%
97,280
+47,157
+94% +$8.67M
LIVN icon
22
LivaNova
LIVN
$4.35B
$17.3M 1.77%
210,529
-193,436
-48% -$13.7M
ANIP icon
23
ANI Pharmaceuticals
ANIP
$1.62B
$16.8M 1.72%
202,907
-77,668
-28% -$6.23M
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.25B
$16.2M 1.66%
1,624,279
-83,820
-5% -$758K
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$34.5B
$15.3M 1.56%
50,672
+23,756
+88% +$7.17M
1
2 3 4 5

Similar funds

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $975M AUM
FM
Family Management New York $975M AUM 23.16% 1-Year Est. Return
PAMI
Perseverance Asset Management International George Town, Cayman Islands $979M AUM 50.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
HIGP
Hill Investment Group Partners St. Louis, Missouri $980M AUM 22.33% 1-Year Est. Return
SCA
Stillwater Capital Advisors Devon, Pennsylvania $981M AUM 31.05% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Parkman Healthcare Partners held 108 positions worth $977M, up 0.74% from $970M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $105M in Q2 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Miscellaneous.

Against the trend, Parkman Healthcare Partners opened a new position in Inhibrx worth $24.3M.

  • Parkman Healthcare Partners's largest Q2 2026 buy was Inhibrx: 256,950 shares worth $24.3M.
  • Parkman Healthcare Partners added most to Viridian Therapeutics in Q2 2026, an estimated $13.2M increase.
  • Parkman Healthcare Partners's biggest Q2 2026 reduction was Stryker, cutting an estimated $27.4M.
  • Parkman Healthcare Partners fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $36.9M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $977M portfolio in Q2 2026.
  • Parkman Healthcare Partners opened 18 new positions and closed 31 in Q2 2026.
  • Parkman Healthcare Partners's portfolio value rose 0.74% quarter-over-quarter to $977M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.